Hiroshima University Graduate School of Biomedical and Health Sciences Department of Pathology [Yukio Takeshima LAB]

Mesothelioma Research

Being Pathology department, we are devoting our times for the accurate pathological diagnosis and aiming as one of the pioneer Research Center for Pathobiological Understanding of Malignant Mesothelioma

Pathological diagnosis of malignant mesothelioma

Malignant mesothelioma show diverse histopathological features, making it more difficult to make accurate diagnosis or differentiating from other cancers. The use of immunohistochemical technique has improved the accuracy of pathological diagnosis in many of cases. However, there are still no proper conscience among the pathologists with expertise in mesothelioma diagnosis in some of the difficult cases (False Negative or False positive) with recent immunohistochemical data interpretations.

In Japan, we found about 15% of misdiagnosis of malignant mesothelioma (Takeshima et al., Lung Cancer, 66(2) : 191-197, 2009) by general pathologists. To improve the accuracy of pathological diagnosis of malignant mesothelioma even by general pathologists who are not expert in mesothelioma diagnosis, search of better immunohistochemical markers are essential.

Gross, cytological, histological and immunohistochemical features
see our publications

Microarray profiling and functional analysis of malignant mesothelioma

Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma.

Malignant mesothelioma is a highly aggressive cancer with poor prognosis and refractory to currently available therapies. Most of the patients with advanced invasive nature are not amenable to surgical resection and/or available anticancer therapy, thus development of novel effective therapeutic regimes is needed. Aberrant expression of microRNAs (miRNAs) has been proposed to contribute to carcinogenesis and aggressiveness of mesothelioma. We analyzed miRNA expression in mesothelioma cell lines using TaqMan miRNA expression array and found significant number of miRNAs, which showed increased or lost expression. We validated the increased expression of miR-182, and miR-183 in mesothelioma cell lines by individual miRNA assays and SmartFlare miRNA probes. We further investigated the miR-1, and miR-214, which were not expressed in mesothelioma cells by real-time RT-PCR. Transfection of mesothelioma cells, ACC-Meso-1 and CRL5915, with miRNA mimic (hsa-miR-1 mimic and hsa-miR-214 mimic) led to inhibition of cell growth, invasion and migration. We paid attention to PIM1, the target gene of both miR-1 and miR-214 miRNAs and which was found overexpressed in mesothelioma cells, and miR-1 and miR-214 mimic transfection of mesothelioma cell lines showed downregulation of PIM1 by western blot analysis. The miRNAs, miR-1 and miR-214, may play a role in carcinogenesis of mesothelioma thus might be considered as candidate therapeutic targets in mesothelioma.

Asbestos exposure as a cause of various cancer

Malignant mesothelioma is an aggressive cancer arising from mesothelial lining of pleura, peritoneum, pericardium, and tunica vaginalis. Asbestos exposure is considered as a principal cause of malignant mesothelioma.

In Japan, the incidence of malignant mesothelioma is increasing year by year and have reached more than 1400 death per year. Many of these patients had history of occupational exposure of asbestos (80~90%) and others areconsidered due to environmental exposure (e.g. residence near asbestos factory).

Our Publications on Mesothelioma

SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.

Nakagiri T, Amatya VJ, Kushitani K, Kambara T, Aoe K, Endo I, Miyata Y, Okada M, Takeshima Y.
Am J Surg Pathol. 2023 Oct 30. doi: 10.1097/PAS.0000000000002147. Online ahead of print.

Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.

Endo I, Amatya VJ, Kushitani K, Nakagiri T, Aoe K, Takeshima Y.
Anticancer Res. 2023 Dec;43(12):5367-5376.

FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling.

Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Aoe K, Takeshima Y.
Anticancer Res. 2023 Sep;43(9):3961-3968.

miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV.

Endo I, Amatya VJ, Kushitani K, Nakagiri T, Aoe K, Takeshima Y.
Pathobiology. 2023;90(4):270-280.

Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.

Sa-Ngiamwibool P, Hamasaki M, Kinoshita Y, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Kasai T, Kushitani K, Takeshima Y, Hiroshima K, Iwasaki A, Nabeshima K.
Lung Cancer. 2023 Jan;175:27-35.

Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.

Sa-Ngiamwibool P, Hamasaki M, Kinoshita Y, Matsumoto S, Sato A, Tsujimura T, Kasai T, Hiroshima K, Kushitani K, Takeshima Y, Kawahara K, Iwasaki A, Nabeshima K.
Ann Diagn Pathol. 2022 Oct;60:152004.

Downregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G1 cell cycle arrest.

Kambara T, Amatya VJ, Kushitani K, Fujii Y, Endo I, Takeshima Y.
Oncol Lett. 2022 Jun;23(6):174.

Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.

Fujii Y, Amatya VJ, Kushitani K, Suzuki R, Kai Y, Kambara T, Takeshima Y.
Oncol Rep. 2022 Feb;47(2):27.

Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Kip1.

Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Fujii Y, Takeshima Y.
Front Oncol. 2022 Jan 19;11:795467.

Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor.

Naka T, Hatanaka Y, Tabata Y, Takasawa A, Akiyama H, Hida Y, Okada H, Hatanaka KC, Mitsuhashi T, Kushitani K, Amatya VJ, Takeshima Y, Inai K, Kaga K, Matsuno Y.
Diagnostics (Basel). 2022 Jan 27;12(2):316.

SOX6 Is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.

Kambara T, Amatya VJ, Kushitani K, Suzuki R, Fujii Y, Kai Y, Miyata Y, Okada M, Takeshima Y.
Am J Surg Pathol. 2020 Sep;44(9):1259-1265.

Inhibition of Mir-18a-3p Reduces Proliferation of Mesothelioma Cells and Sensitizes Them to Cisplatin.

Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, and Takeshima Y.
Oncol Lett. 2020, 19(6):4161-68

Mucin 21 Is a Novel, Negative Immunohistochemical Marker for Epithelioid Mesothelioma for Its Differentiation from Lung Adenocarcinoma.

Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, and Takeshima Y.
Histopathology. 2019, 74(4):545-54

Reply to 'Muc4 Staining in Sarcomatoid Carcinomas' by Berg Et Al.

Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, and Takeshima Y.
Mod Pathol. 2019, 32(1):158

Mir-182 and Mir-183 Promote Cell Proliferation and Invasion by Targeting Foxo1 in Mesothelioma.

Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, and Takeshima Y.
Front Oncol. 2018, 8(446)

Muc4 Immunohistochemistry Is Useful in Distinguishing Epithelioid Mesothelioma from Adenocarcinoma and Squamous Cell Carcinoma of the Lung.

Mawas AS, Amatya VJ, Kushitani K, Kai Y, Miyata Y, Okada M, and Takeshima Y.
Sci Rep. 2018, 8(1):134

Utility of Survivin, Bap1, and Ki-67 Immunohistochemistry in Distinguishing Epithelioid Mesothelioma from Reactive Mesothelial Hyperplasia.

Kushitani K, Amatya VJ, Mawas AS, Suzuki R, Miyata Y, Okada M, Inai K, Kishimoto T, and Takeshima Y.
Oncol Lett. 2018, 15(3):3540-47

Glypican-1 Immunohistochemistry Is a Novel Marker to Differentiate Epithelioid Mesothelioma from Lung Adenocarcinoma.

Amatya VJ, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M, and Takeshima Y.
Mod Pathol. 2018, 31(5):809-15

Pim1 Knockdown Inhibits Cell Proliferation and Invasion of Mesothelioma Cells.

Mawas AS, Amatya VJ, Suzuki R, Kushitani K, Mohi El-Din MM, and Takeshima Y.
Int J Oncol. 2017, 50(3):1029-34

Utility and Pitfalls of Immunohistochemistry in the Differential Diagnosis between Epithelioid Mesothelioma and Poorly Differentiated Lung Squamous Cell Carcinoma.

Kushitani K, Amatya VJ, Okada Y, Katayama Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T, and Takeshima Y.
Histopathology. 2017, 70(3):375-84

Identification of Dab2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation from Pulmonary Adenocarcinoma.

Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, and Takeshima Y.
Am J Surg Pathol. 2017, 41(8):1045-52

Muc4, a Novel Immunohistochemical Marker Identified by Gene Expression Profiling, Differentiates Pleural Sarcomatoid Mesothelioma from Lung Sarcomatoid Carcinoma.

Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, and Takeshima Y.
Mod Pathol. 2017, 30(5):672-81

Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.

Kushitani K, Amatya VJ, Mawas AS, Miyata Y, Okada M, and Takeshima Y.
Pathobiology. 2016, 83(1):33-40

Computed Tomographic Features of Malignant Peritoneal Mesothelioma.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, and Kishimoto T.
Anticancer Res. 2016, 36(3):1067-72

Fatal Pleural Mesothelioma in Japan (2003-2008): Evaluation of Computed Tomography Findings.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, Kishimoto T. Jpn J Radiol. 2016, 34(6):432-8

Pleural Irregularities and Mediastinal Pleural Involvement in Early Stages of Malignant Pleural Mesothelioma and Benign Asbestos Pleural Effusion. Eur J Radiol. 2016, 85(9):1594-600

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, Kishimoto T. Differential Microrna Expression Profiling of Mesothelioma and Expression Analysis of Mir-1 and Mir-214 in Mesothelioma.

Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, and Takeshima Y.
Int J Oncol. 2016, 48(4):1599-607

Histone H2a T120 Phosphorylation Promotes Oncogenic Transformation Via Upregulation of Cyclin D1.

Aihara H, Nakagawa T, Mizusaki H, Yoneda M, Kato M, Doiguchi M, Imamura Y, Higashi M, Ikura T, Hayashi T, Kodama Y, Oki M, Nakayama T, Cheung E, Aburatani H, Takayama KI, Koseki H, Inoue S, Takeshima Y, and Ito T.
Mol Cell. 2016, 64(1):176-88

Treatment and Survival Analyses of Malignant Mesothelioma in Japan.

Gemba K, Fujimoto N, Aoe K, Kato K, Takeshima Y, Inai K, and Kishimoto T.
Acta Oncol. 2013, 52(4):803-8

Cd9 Expression as a Favorable Prognostic Marker for Patients with Malignant Mesothelioma.

Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, and Inai K.
Oncol Rep. 2013, 29(1):21-8

National Survey of Malignant Mesothelioma and Asbestos Exposure in Japan.

Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, and Kishimoto T.
Cancer Sci. 2012, 103(3):483-90

Cd26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma.

Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, and Morimoto C.
Clin Cancer Res. 2012, 18(5):1447-56

Clinical, Radiological, and Pathological Investigation of Asbestosis.

Kishimoto T, Kato K, Arakawa H, Ashizawa K, Inai K, and Takeshima Y.
Int J Environ Res Public Health. 2011, 8(3):899-912

Overexpression of Cd26/Dppiv in Mesothelioma Tissue and Mesothelioma Cell Lines.

Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, and Inai K.
Oncol Rep. 2011, 26(6):1369-75

Myogenic Antigen Expression Is Useful for Differentiation between Epithelioid Mesothelioma and Non-Neoplastic Mesothelial Cells.

Tsukiji H, Takeshima Y, Amatya VJ, Kushitani K, and Inai K.
Histopathology. 2010, 56(7):969-74

Aberrant Promoter Methylation of Wif-1 and Sfrp1, 2, 4 Genes in Mesothelioma.

Kohno H, Amatya VJ, Takeshima Y, Kushitani K, Hattori N, Kohno N, and Inai K.
Oncol Rep. 2010, 24(2):423-31

Clinical Study on Mesothelioma in Japan: Relevance to Occupational Asbestos Exposure.

Kishimoto T, Gemba K, Fujimoto N, Aoe K, Kato K, Takeshima Y, and Inai K.
Am J Ind Med. 2010, 53(11):1081-7

Evaluation of Apoptosis and Immunohistochemical Expression of the Apoptosis-Related Proteins in Mesothelioma.

Jin L, Amatya VJ, Takeshima Y, Shrestha L, Kushitani K, and Inai K.
Hiroshima J Med Sci. 2010, 59(2):27-33

Accuracy of Pathological Diagnosis of Mesothelioma Cases in Japan: Clinicopathological Analysis of 382 Cases.

Takeshima Y, Inai K, Amatya VJ, Gemba K, Aoe K, Fujimoto N, Kato K, and Kishimoto T.
Lung Cancer. 2009, 66(2):191-7

Value of Immunohistochemistry in the Differential Diagnosis of Pleural Sarcomatoid Mesothelioma from Lung Sarcomatoid Carcinoma.

Takeshima Y, Amatya VJ, Kushitani K, Kaneko M, and Inai K.
Histopathology. 2009, 54(6):667-76

Caveolin-1 Is a Novel Immunohistochemical Marker to Differentiate Epithelioid Mesothelioma from Lung Adenocarcinoma.

Amatya VJ, Takeshima Y, Kohno H, Kushitani K, Yamada T, Morimoto C, and Inai K.
Histopathology. 2009, 55(1):10-9

A Useful Antibody Panel for Differential Diagnosis between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases.

Takeshima Y, Amatya VJ, Kushitani K, and Inai K.
Am J Clin Pathol. 2008, 130(5):771-9

Differential Diagnosis of Sarcomatoid Mesothelioma from True Sarcoma and Sarcomatoid Carcinoma Using Immunohistochemistry.

Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, and Inai K.
Pathol Int. 2008, 58(2):75-83

Immunohistochemical Marker Panels for Distinguishing between Epithelioid Mesothelioma and Lung Adenocarcinoma.

Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, and Inai K.
Pathol Int. 2007, 57(4):190-9

Other Research of our Department

Previous Researches of Lung Cancer

MUSTARD GAS & LUNG CANCER

The p53 mutational frequency in the MG-exposed cases is similar to the non-exposed controls and the usual smoking-related lung cancers reported previously. However, the distinctive double mutations (G:C to A:T transition) observed in two cases are unusual and may be related to MG exposure.

p53 mutations in lung cancers from Japanese mustards gas workers.

Takeshima Y, Inai K, Bennett WP, Metcalf RA, Welsh JA, Yonehara S, Hayashi Y, Fujihara M, Yamakido M, Akiyama M, Tokuoka S, Land CE, and Harris CC.
Carcinogenesis (1994) 15 (10): 2075-2079.

ATOMIC BOMB SURVIVOR & LUNG CANCER

The P53 mutations A-BOMB survivors were predominantly transitions (all G:C to A:T) and no G:C to T:A transversions. By contrast, lung cancers from 77 Japanese smokers have a predominance of G:C to T:A transversions.

p53 mutations in lung cancers from non-smoking atomic-bomb survivors.

Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC.
Lancet. 1993 Dec 18-25;342(8886-8887):1520-1.

P53 mutation & 3p, 9p, 17pLOH in Precancerous lesion of LUNG

Evaluation of p53 gene mutation and loss of heterozygosity of 3p, 9p and 17p in precancerous lesions of 29 lung cancer patients.

Nishisaka T, Takeshima Y, Inai K.
Hiroshima J Med Sci. 2000 Jun;49(2):109-16.

Multistep Carcinogenesis of Lung adenocarcinoma

Lung cancer has been increasing rapidly in recent years. The peripheral-type adenocarcinomashowe progression from AAH ( atypical adenomatous hyperplasia ) → BAC ( bronchioles alveolar epithelial carcinoma ) → invasive adenocarcinoma with abnormal accumulation of genetic changes.

Evaluation of p53 gene mutation and loss of heterozygosity of 3p, 9p and 17p in precancerous lesions of 29 lung cancer patients.

Takeshima Y, Yamasaki M, Nishisaka T, Kitaguchi S, Inai K.
Carcinogenesis. 1998 Oct;19(10):1755-61.

Down-regulation of KAI1 messenger RNA expression is not associated with loss of heterozygosity of the KAI1 gene region in lung adenocarcinoma.

Tagawa K, Arihiro K, Takeshima Y, Hiyama E, Yamasaki M, Inai K.
Jpn J Cancer Res. 1999 Sep;90(9):970-6.

Correlation between genetic alterations and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung.

Yamasaki M, Takeshima Y, Fujii S, Kitaguchi S, Matsuura M, Tagawa K, Inai K.
Pathol Int. 2000 Oct;50(10):778-85.

p21WAF1/CIP1 expression in primary lung adenocarcinomas: heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities.

Takeshima Y, Yamasaki M, Nishisaka T, Kitaguchi S, Inai K.
Carcinogenesis. 1998 Oct;19(10):1755-61.

Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung.
Yamasaki M1, Takeshima Y, Fujii S, Matsuura M, Tagawa K, Inai K.

Pathol Int. 2000 Nov;50(11):891-6.

Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.

Awaya H, Takeshima Y, Yamasaki M, Inai K.
Am J Clin Pathol. 2004 May;121(5):644-53.

Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma.
Awaya H, Takeshima Y, Amatya VJ, Ishida H, Yamasaki M, Kohno N, Inai K.

Pathol Int. 2005 Jan;55(1):14-8.

Abberant methylation of tumor suprresor genes in lung adenocarcinoma & squamous cell carcinoma

Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung.

Awaya H, Takeshima Y, Amatya VJ, Furonaka O, Tagawa K, Kohno N, Inai K.
Pathol Int. 2004 Jul;54(7):486-9.

Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma.

Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K.
Pathol Int. 2004 Aug;54(8):549-55.

Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.

Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K.
Pathol Int. 2005 Jun;55(6):303-9.

Welcome to Our Website

Mesothelioma Research

Being Pathology department, we are devoting our times for the accurate pathological diagnosis and aiming as one of the pioneer Research Center for Pathobiological Understanding of Malignant Mesothelioma

Pathological diagnosis of malignant mesothelioma

Microarray profiling and functional analysis of malignant mesothelioma

Asbestos exposure as a cause of various cancer

Our Publications on Mesothelioma

Other Research of our Department

Previous Researches of Lung Cancer

MUSTARD GAS & LUNG CANCER

The p53 mutational frequency in the MG-exposed cases is similar to the non-exposed controls and the usual smoking-related lung cancers reported previously. However, the distinctive double mutations (G:C to A:T transition) observed in two cases are unusual and may be related to MG exposure.

p53 mutations in lung cancers from Japanese mustards gas workers.

ATOMIC BOMB SURVIVOR & LUNG CANCER

The P53 mutations A-BOMB survivors were predominantly transitions (all G:C to A:T) and no G:C to T:A transversions. By contrast, lung cancers from 77 Japanese smokers have a predominance of G:C to T:A transversions.

p53 mutations in lung cancers from non-smoking atomic-bomb survivors.

P53 mutation & 3p, 9p, 17pLOH in Precancerous lesion of LUNG

Evaluation of p53 gene mutation and loss of heterozygosity of 3p, 9p and 17p in precancerous lesions of 29 lung cancer patients.

Multistep Carcinogenesis of Lung adenocarcinoma

Lung cancer has been increasing rapidly in recent years. The peripheral-type adenocarcinomashowe progression from AAH ( atypical adenomatous hyperplasia ) → BAC ( bronchioles alveolar epithelial carcinoma ) → invasive adenocarcinoma with abnormal accumulation of genetic changes.

Evaluation of p53 gene mutation and loss of heterozygosity of 3p, 9p and 17p in precancerous lesions of 29 lung cancer patients.

Down-regulation of KAI1 messenger RNA expression is not associated with loss of heterozygosity of the KAI1 gene region in lung adenocarcinoma.

Correlation between genetic alterations and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung.

p21WAF1/CIP1 expression in primary lung adenocarcinomas: heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities.

Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung. Yamasaki M1, Takeshima Y, Fujii S, Matsuura M, Tagawa K, Inai K.

Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.

Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma. Awaya H, Takeshima Y, Amatya VJ, Ishida H, Yamasaki M, Kohno N, Inai K.

Abberant methylation of tumor suprresor genes in lung adenocarcinoma & squamous cell carcinoma

Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung.

Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma.

Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.

Recent Projects

Epithelioid Mesothelioma verus Squamous Cell Carcinoma of Lung

Epithelioid Mesothelioma verus Adenocarcinoma of Lung

Sarcomatoid Mesothelioma verus Pleomorphic Carcinoma of Lung

MiRNA expression Profiling of Malignant Mesothelioma

Functional Analysis of downregulated MiRNA expression in Mesothelioma

Yukio Takeshima

Vishwa J. Amatya

Kei Kushitani

TETSUYA NAKAGIRI

KOHEI AOE

OKADA SHOGO

Mayumi KanekoDepartment of Pathology, Hiroshima City Asa Hospital, Hiroshima

IHIRO ENDO PhD

TAKAHIRO KAMBARA MD, PhD

YUTARO FUJII PhD

YUICHIRO KAI MD, PhD

YUI SUZUKI PhD

Masatsugu Kuraoka MD, PhD

Amany Sayed Mawas BVSc, PhD

Medical Students 2024

Hayama Soichiro

Medical Students 2023

Ono Hiroki Okada Shogo

Medical Students 2021

Koichi Takeda

Medical Students 2020

Ihiro Endo Yoshifumi Sakurai

Medical Students 2019

Takahiro Nomura Masatoshi Fukuya

Medical Students 2018

Yutaro Fujii Takuya Aikawa

Medical Students 2017

Imura Yusuke Yano Daisuke

Medical Students 2016

Rui Suzuki Shin Miyahara Ikuko Ohoka

Medical Students 2015

Yasuko Okada Katayama Yuya Gurita Tomoyuki Takagi Yuki

Medical Students 2014

Satoki Morita Yuuki Naito Hiroto Shimajiri

Medical Students 2013

Hiroyuki Aiba Yuusuke Takahashi

Medical Students 2012

Yosuke Kagawa Toshiwo Min Yuta Kuhara

Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung.
Yamasaki M1, Takeshima Y, Fujii S, Matsuura M, Tagawa K, Inai K.

Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma.
Awaya H, Takeshima Y, Amatya VJ, Ishida H, Yamasaki M, Kohno N, Inai K.

Mayumi Kaneko

Department of Pathology,
Hiroshima City Asa Hospital, Hiroshima

IHIRO ENDO

PhD

TAKAHIRO KAMBARA

MD, PhD

YUTARO FUJII

PhD

YUICHIRO KAI

MD, PhD

YUI SUZUKI

PhD

Masatsugu Kuraoka

MD, PhD

Amany Sayed Mawas

BVSc, PhD

Ono Hiroki
Okada Shogo

Ihiro Endo
Yoshifumi Sakurai

Takahiro Nomura
Masatoshi Fukuya

Yutaro Fujii
Takuya Aikawa

Imura Yusuke
Yano Daisuke

Rui Suzuki
Shin Miyahara
Ikuko Ohoka

Yasuko Okada
Katayama Yuya
Gurita Tomoyuki
Takagi Yuki

Satoki Morita
Yuuki Naito
Hiroto Shimajiri

Hiroyuki Aiba
Yuusuke Takahashi

Yosuke Kagawa
Toshiwo Min
Yuta Kuhara